ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Lamivudine Teva 100 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 100 mg lamivudine
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Film-coated tablet
Orange, capsule shaped, biconvex film-coated tablet – engraved with “L 100” on one side and plain on the other.

4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Lamivudine Teva is indicated for the treatment of chronic hepatitis B in adults with:
- compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see section 5.1).
- decompensated liver disease in combination with a second agent without cross-resistance to lamivudine (see section 4.2).

4.2 Posology and method of administration
Therapy with Lamivudine Teva should be initiated by a physician experienced in the management of chronic hepatitis B.

Posology
Adults
The recommended dosage of Lamivudine Teva is 100 mg once daily.

In patients with decompensated liver disease, lamivudine should always be used in combination with a second agent, without cross-resistance to lamivudine, to reduce the risk of resistance and to achieve rapid viral suppression.

Duration of treatment
The optimal duration of treatment is unknown.
- In patients with HBeAg positive chronic hepatitis B (CHB) without cirrhosis, treatment should be administered for at least 6-12 months after HBeAg seroconversion (HBeAg and HBV DNA loss with HBeAb detection) is confirmed, to limit the risk of virological relapse, or until HBsAg seroconversion or there is loss of efficacy (see section 4.4). Serum ALT and HBV DNA levels
should be followed regularly after treatment discontinuation to detect any late virological relapse.

- In patients with HBeAg negative CHB (pre-core mutant) without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy. With prolonged treatment, regular reassessment is recommended to confirm that continuation of the selected therapy remains appropriate for the patient.
- In patients with decompensated liver disease or cirrhosis and in liver transplant recipients, treatment cessation is not recommended (see section 5.1).

If lamivudine is discontinued, patients should be periodically monitored for evidence of recurrent hepatitis (see section 4.4).

Clinical resistance
In patients with either HBeAg positive or HBeAg negative CHB, the development of YMDD (tyrosine-methionine-aspartate-aspartate) mutant HBV may result in a diminished therapeutic response to lamivudine, indicated by a rise in HBV DNA and ALT from previous on-treatment levels. In order to reduce the risk of resistance in patients receiving lamivudine monotherapy, a switch to or addition of an alternative agent without cross-resistance to lamivudine based on therapeutic guidelines should be considered if serum HBV DNA remains detectable at or beyond 24 weeks of treatment (see section 5.1).

For the treatment of patients who are co-infected with HIV and are currently receiving or plan to receive treatment with lamivudine or the combination lamivudine-zidovudine, the dose of lamivudine prescribed for HIV infection (usually 150 mg/twice daily in combination with other antiretrovirals) should be maintained.

Special populations

Renal impairment
Lamivudine serum concentrations (AUC) are increased in patients with moderate to severe renal impairment due to decreased renal clearance. The dosage should therefore be reduced for patients with a creatinine clearance of < 50 ml/minute. Lamivudine Teva is not suitable for patients who require doses below 100 mg.

Data available in patients undergoing intermittent haemodialysis (for less than or equal to 4 hrs dialysis 2-3 times weekly), indicate that following the initial dosage reduction of lamivudine to correct for the patient’s creatinine clearance, no further dosage adjustments are required while undergoing dialysis.

Hepatic impairment
Data obtained in patients with hepatic impairment, including those with end-stage liver disease awaiting transplant, show that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction. Based on these data, no dose adjustment is necessary in patients with hepatic impairment unless accompanied by renal impairment.

Elderly
In elderly patients, normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of < 50 ml/min.

Paediatric population
The safety and efficacy of Lamivudine Teva in infants, children and adolescents aged below 18 years have not been established. Currently available data are described in sections 4.4 and 5.1 but no recommendation on a posology can be made.

Method of administration
Oral use.
Lamivudine Teva can be taken with or without food.
4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Exacerbations of hepatitis

Exacerbations on treatment
Spontaneous exacerbations in chronic hepatitis B are relatively common and are characterised by transient increases in serum ALT. After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV DNA levels decline. In patients with compensated liver disease, these increases in serum ALT were generally not accompanied by an increase in serum bilirubin concentrations or signs of hepatic decompensation.

HBV viral subpopulations with reduced susceptibility to lamivudine (YMDD mutant HBV) have been identified with extended therapy. In some patients the development of YMDD mutant HBV can lead to exacerbation of hepatitis, primarily detected by serum ALT elevations and re-emergence of HBV DNA (see section 4.2). In patients who have YMDD mutant HBV, a switch to or addition of an alternative agent without cross resistance to lamivudine based on therapeutic guidelines should be considered (see section 5.1).

Exacerbations after treatment discontinuation
Acute exacerbation of hepatitis has been observed in patients who have discontinued hepatitis B therapy and is usually detected by serum ALT elevations and re-emergence of HBV DNA. In the controlled Phase III trials with no-active-treatment follow-up, the incidence of post-treatment ALT elevations (more than 3 times baseline) was higher in lamivudine-treated patients (21%) compared with those receiving placebo (8%). However, the proportion of patients who had post-treatment elevations associated with bilirubin elevations was low and similar in both treatment arms (see Table 3 in section 5.1). For lamivudine-treated patients, the majority of post-treatment ALT elevations occurred between 8 and 12 weeks post-treatment. Most events have been self-limiting, however some fatalities have been observed. If Lamivudine Teva is discontinued, patients should be periodically monitored both clinically and by assessment of serum liver function tests (ALT and bilirubin levels), for at least four months, and then as clinically indicated.

Exacerbations in patients with decompensated cirrhosis
Transplantation recipients and patients with decompensated cirrhosis are at greater risk from active viral replication. Due to the marginal liver function in these patients, hepatitis reactivation at discontinuation of lamivudine or loss of efficacy during treatment may induce severe and even fatal decompensation. These patients should be monitored for clinical, virological and serological parameters associated with hepatitis B, liver and renal function, and antiviral response during treatment (at least every month), and, if treatment is discontinued for any reason, for at least 6 months after treatment. Laboratory parameters to be monitored should include (as a minimum) serum ALT, bilirubin, albumin, blood urea nitrogen, creatinine, and virological status: HBV antigen/antibody, and serum HBV DNA concentrations when possible. Patients experiencing signs of hepatic insufficiency during or post-treatment should be monitored more frequently as appropriate.

For patients who develop evidence of recurrent hepatitis post-treatment, there are insufficient data on the benefits of re-initiation of lamivudine treatment.

Mitochondrial dysfunction
Nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in infants exposed in utero and/or post-natally to nucleoside analogues. The main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlipasemia). Some late-
onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour). The neurological disorders might be transient or permanent. Any child exposed in utero to nucleoside and nucleotide analogues, should have clinical and laboratory follow-up and should be fully investigated for possible mitochondrial dysfunction in cases which have relevant signs or symptoms.

**Paediatric population**
Lamivudine has been administered to children (2 years and above) and adolescents with compensated chronic hepatitis B. However, due to limitations of the data, the administration of lamivudine to this patient population is not currently recommended (see section 5.1).

**Delta hepatitis or hepatitis C**
The efficacy of lamivudine in patients co-infected with Delta hepatitis or hepatitis C has not been established and caution is advised.

**Immunosuppressive treatments**
Data are limited on the use of lamivudine in HBeAg negative (pre-core mutant) patients and in those receiving concurrent immunosuppressive regimes, including cancer chemotherapy. Lamivudine should be used with caution in these patients.

**Monitoring**
During treatment with Lamivudine Teva patients should be monitored regularly. Serum ALT and HBV DNA levels should be monitored at 3 month intervals and in HBeAg positive patients HBeAg should be assessed every 6 months.

**HIV co-infection**
For the treatment of patients who are co-infected with HIV and are currently receiving or plan to receive treatment with lamivudine or the combination lamivudine-zidovudine, the dose of lamivudine prescribed for HIV infection (usually 150 mg/twice daily in combination with other antiretrovirals) should be maintained. For HIV co-infected patients not requiring anti-retroviral therapy, there is a risk of HIV mutation when using lamivudine alone for treating chronic hepatitis B.

**Transmission of hepatitis B**
There is no information available on maternal-foetal transmission of hepatitis B virus in pregnant women receiving treatment with lamivudine. The standard recommended procedures for hepatitis B virus immunisation in infants should be followed.

Patients should be advised that therapy with lamivudine has not been proven to reduce the risk of transmission of hepatitis B virus to others and therefore, appropriate precautions should still be taken.

**Interactions with other medicinal products**
Lamivudine Teva should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine (see section 4.5).

The combination of lamivudine with cladribine is not recommended (see section 4.5).

**Excipient**

*Sodium*
This medicinal product contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially “sodium-free”.

### 4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have only been performed in adults.
The likelihood of metabolic interactions is low due to limited metabolism and plasma protein binding and almost complete renal elimination of unchanged substance.

Lamivudine is predominantly eliminated by active organic cationic secretion. The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are eliminated only in part by this mechanism and were shown not to interact with lamivudine.

Substances shown to be predominately excreted either via the active organic anionic pathway, or by glomerular filtration are unlikely to yield clinically significant interactions with lamivudine. Administration of trimethoprim/sulphamethoxazole 160 mg/800 mg increased lamivudine exposure by about 40%. Lamivudine had no effect on the pharmacokinetics of trimethoprim or sulphamethoxazole. However, unless the patient has renal impairment, no dosage adjustment of lamivudine is necessary.

A modest increase in C\textsubscript{max} (28%) was observed for zidovudine when administered with lamivudine, however overall exposure (AUC) was not significantly altered. Zidovudine had no effect on the pharmacokinetics of lamivudine (see section 5.2).

Lamivudine has no pharmacokinetic interaction with alpha-interferon when the two medicinal products are concurrently administered. There were no observed clinically significant adverse interactions in patients taking lamivudine concurrently with commonly used immunosuppressant medicinal products (e.g. cyclosporin A). However, formal interaction studies have not been performed.

Emtricitabine
Due to similarities, Lamivudine Teva should not be administered concomitantly with other cytidine analogues, such as emtricitabine. Moreover, Lamivudine Teva should not be taken with any other medicinal products containing lamivudine (see section 4.4).

Cladribine
\textit{In vitro} lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also support a possible interaction between lamivudine and cladribine. Therefore, the concomitant use of lamivudine with cladribine is not recommended (see section 4.4).

Sorbitol
Co-administration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (Adult HIV daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC\textsubscript{∞}) and 28%, 52%, and 55% in the C\textsubscript{max} of lamivudine in adults. When possible, avoid chronic co-administration of Lamivudine Teva with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol, maltitol). Consider more frequent monitoring of HBV viral load when chronic co-administration cannot be avoided.

4.6 Fertility, pregnancy and lactation

Pregnancy
Animal studies with lamivudine showed an increase in early embryonic deaths in rabbits but not in rats (see section 5.3). Placental transfer of lamivudine has been shown to occur in humans.

Available human data from the Antiretroviral Pregnancy Registry reporting more than 1000 outcomes from first trimester and more than 1000 outcomes from second and third trimester exposure in pregnant women indicate no malformative and foeto/neonatal effect. Less than 1% of these women have been treated for HBV, whereas the majority was treated for HIV at higher doses and with other concomitant medications. Lamivudine Teva can be used during pregnancy if clinically needed.
For patients who are being treated with lamivudine and subsequently become pregnant consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of lamivudine.

**Breast-feeding**
Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed infants of mothers treated for HIV are very low (less than 4% of maternal serum concentrations) and progressively decrease to undetectable levels when breastfed infants reach 24 weeks of age. The total amount of lamivudine ingested by a breastfed infant is very low and is therefore likely to result in exposures exerting a sub-optimal antiviral effect. Maternal hepatitis B is not a contraindication to breast-feeding if the newborn is adequately managed for hepatitis B prevention at birth, and there is no evidence that the low concentration of lamivudine in human milk leads to adverse reactions in breastfed infants. Therefore breastfeeding may be considered in breast-feeding mothers being treated with lamivudine for HBV taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. Where there is maternal transmission of HBV, despite adequate prophylaxis, consideration should be given to discontinuing breastfeeding to reduce the risk of the emergence of lamivudine resistant mutants in the infant.

**Fertility**
Reproductive studies in animals have shown no effect on male or female fertility (see section 5.3).

**Mitochondrial dysfunction:**
Nucleoside and nucleotide analogues have been demonstrated *in vitro* and *in vivo* to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in infants exposed in utero and/or post-natally to nucleoside analogues (see section 4.4).

**4.7 Effects on ability to drive and use machines**
Patients should be informed that malaise and fatigue have been reported during treatment with lamivudine. The clinical status of the patient and the adverse reaction profile of lamivudine should be borne in mind when considering the patient's ability to drive or operate machinery.

**4.8 Undesirable effects**

**Summary of the safety profile**
The incidence of adverse reactions and laboratory abnormalities (with the exception of elevations of ALT and CPK, see below) were similar between placebo and lamivudine treated patients. The most common adverse reactions reported were malaise and fatigue, respiratory tract infections, throat and tonsil discomfort, headache, abdominal discomfort and pain, nausea, vomiting and diarrhoea.

**Tabulated list of adverse reactions**
Adverse reactions are listed below by system organ class and frequency. Frequency categories are only assigned to those adverse reactions considered to be at least possibly causally related to lamivudine. Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100), rare (≥ 1/10,000 to < 1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

The frequency categories assigned to the adverse reactions are mainly based on experience from clinical trials including a total of 1,171 patients with chronic hepatitis B receiving lamivudine at 100 mg.

<table>
<thead>
<tr>
<th>Blood and lymphatic system disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not known</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Metabolism and nutrition disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very rare</td>
</tr>
<tr>
<td>Lactic acidosis</td>
</tr>
</tbody>
</table>

| Immune system disorders:          |

7
<table>
<thead>
<tr>
<th>Frequency</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare</td>
<td>Angioedema</td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>ALT elevations (see section 4.4)</td>
</tr>
<tr>
<td>Exacerbations of hepatitis, primarily detected by serum ALT elevations, have been reported ‘on-treatment’ and following lamivudine withdrawal. Most events have been self-limited, however fatalities have been observed very rarely (see section 4.4).</td>
<td></td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Rash, pruritus</td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Elevations of CPK</td>
</tr>
<tr>
<td>Common</td>
<td>Muscle disorders, including myalgia and cramps*</td>
</tr>
<tr>
<td>Not known</td>
<td>Rhabdomyolysis</td>
</tr>
</tbody>
</table>

* In Phase III studies frequency observed in the lamivudine treatment group was not greater than observed in the placebo group

**Paediatric population**
Based on limited data in children aged 2 to 17 years, there were no new safety issues identified compared to adults.

**Other special populations**
In patients with HIV infection, cases of pancreatitis and peripheral neuropathy (or paresthesia) have been reported. In patients with chronic hepatitis B there was no observed difference in incidence of these events between placebo and lamivudine treated patients.

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

**4.9 Overdose**

No specific signs or symptoms have been identified following acute overdose with lamivudine, apart from those listed as adverse reactions.

If overdose occurs the patient should be monitored and standard supportive treatment applied as required. Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group - Antivirals for systemic use, nucleoside and nucleotide reverse transcriptase inhibitors, ATC Code: J05AF05.

**Mechanism of action**

Lamivudine is an antiviral agent which is active against hepatitis B virus in all cell lines tested and in experimentally infected animals.
Lamivudine is metabolised by both infected and uninfected cells to the triphosphate (TP) derivative which is the active form of the parent compound. The intracellular half life of the triphosphate in hepatocytes is 17-19 hours in vitro. Lamivudine-TP acts as a substrate for the HBV viral polymerase.

The formation of further viral DNA is blocked by incorporation of lamivudine-TP into the chain and subsequent chain termination.

Lamivudine-TP does not interfere with normal cellular deoxynucleotide metabolism. It is also only a weak inhibitor of mammalian DNA polymerases alpha and beta. Furthermore, lamivudine-TP has little effect on mammalian cell DNA content.

In assays relating to potential substance effects on mitochondrial structure and DNA content and function, lamivudine lacked appreciable toxic effects. It has a very low potential to decrease mitochondrial DNA content, is not permanently incorporated into mitochondrial DNA, and does not act as an inhibitor of mitochondrial DNA polymerase gamma.

Clinical efficacy and safety

Experience in patients with HBeAg positive CHB and compensated liver disease

In controlled studies, 1 year of lamivudine therapy significantly suppressed HBV DNA replication [34-57 % of patients were below the assay detection limits (Abbott Genostics solution hybridization assay, LLOD < 1.6 pg/ml)}, normalised ALT level (40-72 % of patients), induced HBeAg seroconversion (HBeAg loss and HBeAb detection with HBV DNA loss [by conventional assay], 16-18 % of patients), improved histology (38-52 % of patients had a ≥ 2 point decrease in the Knodell Histologic Activity Index [HAI]) and reduced progression of fibrosis (in 3-17 % of patients) and progression to cirrhosis.

Continued lamivudine treatment for an additional 2 years in patients who had failed to achieve HBeAg seroconversion in the initial 1 year controlled studies resulted in further improvement in bridging fibrosis. In patients with YMDD mutant HBV, 41/82 (50 %) patients had improvement in liver inflammation and 40/56 (71 %) patients without YMDD mutant HBV had improvement. Improvement in bridging fibrosis occurred in 19/30 (63 %) patients without YMDD mutant and 22/44 (50 %) patients with the mutant. Five percent (3/56) of patients without the YMDD mutant and 13 % (11/82) of patients with YMDD mutant showed worsening in liver inflammation compared to pre-treatment. Progression to cirrhosis occurred in 4/68 (6 %) patients with the YMDD mutant, whereas no patients without the mutant progressed to cirrhosis.

In an extended treatment study in Asian patients (NUCB3018) the HBeAg seroconversion rate and ALT normalisation rate at the end of the 5 year treatment period was 48 % (28/58) and 47 % (15/32), respectively. HBeAg seroconversion was increased in patients with elevated ALT levels; 77 % (20/26) of patients with pre-treatment ALT > 2 x ULN seroconverted. At the end of 5 years, all patients had HBV DNA levels that were undetectable or lower than pre-treatment levels.

Further results from the trial by YMDD mutant status are summarised in Table 1.

Table 1: Efficacy results 5 years by YMDD status (Asian Study) NUCB3018

<table>
<thead>
<tr>
<th>YMDD mutant HBV status</th>
<th>Subjects, % (no.)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>YMDD&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>HBeAg seroconversion</td>
<td></td>
</tr>
<tr>
<td>- All patients</td>
<td>38 (15/40)</td>
</tr>
<tr>
<td>- Baseline ALT ≤ 1 x ULN&lt;sup&gt;1&lt;/sup&gt;</td>
<td>9 (1/11)</td>
</tr>
<tr>
<td>- Baseline ALT &gt; 2 x ULN</td>
<td>60 (9/15)</td>
</tr>
<tr>
<td>Undetectable HBV DNA</td>
<td></td>
</tr>
</tbody>
</table>

 Patients designated as YMDD mutant were those with ≥5% YMDD mutant HBV at any annual time-point during the 5-year period. Patients categorised as non-YMDD mutant were those with > 95% wild-type HBV at all annual time-points during the 5-year study period.

1 Upper limit of normal
2 Abbott Genostics solution hybridisation assay (LLOD < 1.6 pg/ml)
3 Chiron Quantiplex assay (LLOD 0.7 Meq/ml)

Comparative data according to YMDD status were also available for histological assessment but only up to three years. In patients with YMDD mutant HBV, 18/39 (46%) had improvements in necroinflammatory activity and 9/39 (23%) had worsening. In patients without the mutant, 20/27 (74%) had improvements in necroinflammatory activity and 2/27 (7%) had worsening.

Following HBeAg seroconversion, serologic response and clinical remission are generally durable after stopping lamivudine. However, relapse following seroconversion can occur. In a long-term follow-up study of patients who had previously seroconverted and discontinued lamivudine, late virological relapse occurred in 39% of the subjects. Therefore, following HBeAg seroconversion, patients should be periodically monitored to determine that serologic and clinical responses are being maintained. In patients who do not maintain a sustained serological response, consideration should be given to retreatment with either lamivudine or an alternative antiviral agent for resumption of clinical control of HBV.

In patients followed for up to 16 weeks after discontinuation of treatment at one year, post-treatment ALT elevations were observed more frequently in patients who had received lamivudine than in patients who had received placebo. A comparison of post-treatment ALT elevations between weeks 52 and 68 in patients who discontinued lamivudine at week 52 and patients in the same studies who received placebo throughout the treatment course is shown in Table 2. The proportion of patients who had post-treatment ALT elevations in association with an increase in bilirubin levels was low and similar in patients receiving either lamivudine or placebo.

**Table 2: Post-treatment ALT Elevations in 2 Placebo-Controlled Studies in Adults**

<table>
<thead>
<tr>
<th>Abnormal Value</th>
<th>Patients with ALT Elevation/ Patients with Observations*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lamivudine</td>
</tr>
<tr>
<td>ALT ≥ 2 x baseline value</td>
<td>37/137 (27%)</td>
</tr>
<tr>
<td>ALT ≥ 3 x baseline value†</td>
<td>29/137 (21%)</td>
</tr>
<tr>
<td>ALT ≥ 2 x baseline value and absolute ALT &gt; 500 IU/l</td>
<td>21/137 (15%)</td>
</tr>
</tbody>
</table>
ALT ≥2 x baseline value; and bilirubin >2 x ULN and ≥2 x baseline value

1/137 (0.7 %)  
1/116 (0.9 %)

*Each patient may be represented in one or more category.  
Comparable to a Grade 3 toxicity in accordance with modified WHO criteria.  
ULN = Upper limit of normal.

Experience in patients with HBeAg negative CHB:
Initial data indicate the efficacy of lamivudine in patients with HBeAg negative CHB is similar to patients with HBeAg positive CHB, with 71 % of patients having HBV DNA suppressed below the detection limit of the assay, 67 % ALT normalisation and 38 % with improvement in HAI after one year of treatment. When lamivudine was discontinued, the majority of patients (70 %) had a return of viral replication. Data is available from an extended treatment study in HBeAg negative patients (NUCAB3017) treated with lamivudine. After two years of treatment in this study, ALT normalisation and undetectable HBV DNA occurred in 30/69 (43 %) and 32/68 (47 %) patients respectively and improvement in necroinflammatory score in 18/49 (37 %) patients. In patients without YMDD mutant HBV, 14/22 (64 %) showed improvement in necroinflammatory score and 1/22 (5 %) patients worsened compared to pre-treatment. In patients with the mutant, 4/26 (15 %) patients showed improvement in necroinflammatory score and 8/26 (31 %) patients worsened compared to pre-treatment. No patients in either group progressed to cirrhosis.

Frequency of emergence of YMDD mutant HBV and impact on the treatment response:
Lamivudine monotherapy results in the selection of YMDD mutant HBV in approximately 24 % of patients following one year of therapy, increasing to 69 % following 5 years of therapy. Development of YMDD mutant HBV is associated with reduced treatment response in some patients, as evidenced by increased HBV DNA levels and ALT elevations from previous on-therapy levels, progression of signs and symptoms of hepatitis disease and/or worsening of hepatic necroinflammatory findings. Given the risk of YMDD mutant HBV, maintenance of lamivudine monotherapy is not appropriate in patients with detectable serum HBV DNA at or beyond 24 weeks of treatment (see section 4.4).

In a double-blind study in CHB patients with YMDD mutant HBV and compensated liver disease (NUC20904), with a reduced virological and biochemical response to lamivudine (n=95), the addition of adefovir dipivoxil 10 mg once daily to ongoing lamivudine 100 mg for 52 weeks resulted in a median decrease in HBV DNA of 4.6 log₁₀ copies/ml compared to a median increase of 0.3 log₁₀ copies/ml in those patients receiving lamivudine monotherapy. Normalisation of ALT levels occurred in 31 % (14/45) of patients receiving combined therapy versus 6 % (3/47) receiving lamivudine alone. Viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 with patients having continued improvement in virologic and biochemical responses.

In a retrospective study to determine the factors associated with HBV DNA breakthrough, 159 Asian HBeAg-positive patients were treated with lamivudine and followed up for a median period of almost 30 months. Those with HBV DNA levels greater than 200 copies/mL at 6 months (24 weeks) of lamivudine therapy had a 60 % chance of developing the YMDD mutant compared with 8 % of those with HBV DNA levels less than 200 copies/mL at 24 weeks of lamivudine therapy. The risk for developing YMDD mutant was 63% versus 13% with a cut off of 1000 copies/ml (NUCB3009 and NUCB3018).

Experience in patients with decompensated liver disease:
Placebo controlled studies have been regarded as inappropriate in patients with decompensated liver disease, and have not been undertaken. In non-controlled studies, where lamivudine was administered prior to and during transplantation, effective HBV DNA suppression and ALT normalisation was demonstrated. When lamivudine therapy was continued post transplantation there was reduced graft re-infection by HBV, increased HBsAg loss and on one-year survival rate of 76-100 %.
As anticipated due to the concomitant immunosuppression, the rate of emergence of YMDD mutant HBV after 52 weeks treatment was higher (36%-64%) in the liver transplant population than in the immunocompetent CHB patients (14%-32%).

Forty patients (HBeAg negative or HBeAg positive) with either decompensated liver disease or recurrent HBV following liver transplantation and YMDD mutant were enrolled into an open label arm of study NUC20904. Addition of 10 mg adefovir dipivoxil once daily to ongoing lamivudine 100 mg for 52 weeks resulted in a median decrease in HBV DNA of 4.6 log10 copies/ml.

Improvement in liver function was also seen after one year of therapy. This degree of viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 and most patients had improved markers of liver function and continued to derive clinical benefit.

**Experience in CHB patients with advanced fibrosis or cirrhosis:**
In a placebo-controlled study in 651 patients with clinically compensated chronic hepatitis B and histologically confirmed fibrosis or cirrhosis, lamivudine treatment (median duration 32 months) significantly reduced the rate of overall disease progression (34/436, 7.8 % for lamivudine versus 38/215, 17.7 % for placebo, p=0.001), demonstrated by a significant reduction in the proportion of patients having increased Child-Pugh scores (15/436, 3.4 % versus 19/215, 8.8 %, p=0.023) or developing hepatocellular carcinoma (17/436, 3.9 % versus 16/215, 7.4 %, p=0.047). The rate of overall disease progression in the lamivudine group was higher for subjects with detectable YMDD mutant HBV DNA (23/209, 11 %) compared to those without detectable YMDD mutant HBV (11/221, 5 %). However, disease progression in YMDD subjects in the lamivudine group was lower than the disease progression in the placebo group (23/209, 11 % versus 38/214, 18 % respectively). Confirmed HBeAg seroconversion occurred in 47 % (118/252) of subjects treated with lamivudine and 93 % (320/345) of subjects receiving lamivudine became HBV DNA negative (VERSANT [version 1], bDNA assay, LLOD < 0.7 MEq/ml) during the study.

**Experience in children and adolescents:**
Lamivudine has been administered to children and adolescents with compensated CHB in a placebo controlled study of 286 patients aged 2 to 17 years. This population primarily consisted of children with minimal hepatitis B. A dose of 3 mg/kg once daily (up to a maximum of 100 mg daily) was used in children aged 2 to 11 years and a dose of 100 mg once daily in adolescents aged 12 years and above. This dose needs to be further substantiated. The difference in the HBeAg seroconversion rates (HBeAg and HBV DNA loss with HBeAb detection) between placebo and lamivudine was not statistically significant in this population (rates after one year were 13 % (12/95) for placebo versus 22 % (42/191) for lamivudine; p=0.057). The incidence of YMDD mutant HBV was similar to that observed in adults, ranging from 19 % at week 52 up to 45 % in patients treated continuously for 24 months.

### 5.2 Pharmacokinetic properties

**Absorption**

Lamivudine is well absorbed from the gastrointestinal tract, and the bioavailability of oral lamivudine in adults is normally between 80 and 85 %. Following oral administration, the mean time ($t_{max}$) to maximal serum concentrations ($C_{max}$) is about an hour. At therapeutic dose levels i.e. 100 mg once daily, $C_{max}$ is in the order of 1.1-1.5 µg/ml and trough levels were 0.015-0.020 µg/ml.

Co-administration of lamivudine with food resulted in a delay of $t_{max}$ and a lower $C_{max}$ (decreased by up to 47 %). However, the extent (based on the AUC) of lamivudine absorbed was not influenced, therefore lamivudine can be administered with or without food.

**Distribution**

From intravenous studies the mean volume of distribution is 1.3 l/kg. Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays low plasma protein binding to albumin.
Limited data shows lamivudine penetrates the central nervous system and reaches the cerebro-spinal fluid (CSF). The mean lamivudine CSF/serum concentration ratio 2-4 hours after oral administration was approximately 0.12.

**Biotransformation**

Lamivudine is predominately cleared by renal excretion of unchanged substance. The likelihood of metabolic substance interactions with lamivudine is low due to the small (5-10%) extent of hepatic metabolism and the low plasma protein binding.

**Elimination**

The mean systemic clearance of lamivudine is approximately 0.3 l/h/kg. The observed half-life of elimination is 18 to 19 hours. The majority of lamivudine is excreted unchanged in the urine via glomerular filtration and active secretion (organic cationic transport system). Renal clearance accounts for about 70% of lamivudine elimination.

**Special populations**

Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction. Dose reduction in patients with a creatinine clearance of < 50 ml/min is necessary (see section 4.2).

The pharmacokinetics of lamivudine are unaffected by hepatic impairment. Limited data in patients undergoing liver transplantation show that impairment of hepatic function does not impact significantly on the pharmacokinetics of lamivudine unless accompanied by renal dysfunction.

In elderly patients the pharmacokinetic profile of lamivudine suggests that normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of < 50 ml/min (see section 4.2).

5.3 **Preclinical safety data**

Administration of lamivudine in animal toxicity studies at high doses was not associated with any major organ toxicity. At the highest dosage levels, minor effects on indicators of liver and kidney function were seen together with occasional reduction in liver weights. Reduction of erythrocytes and neutrophil counts were identified as the effects most likely to be of clinical relevance. These events were seen infrequently in clinical studies.

Lamivudine was not mutagenic in bacterial tests but, like many nucleoside analogues showed activity in an in vitro cytogenetic assay and the mouse lymphoma assay. Lamivudine was not genotoxic in vivo at doses that gave plasma concentrations around 60-70 times higher than the anticipated clinical plasma levels. As the in vitro mutagenic activity of lamivudine could not be confirmed by in vivo tests, it is concluded that lamivudine should not represent a genotoxic hazard to patients undergoing treatment.

Reproductive studies in animals have not shown evidence of teratogenicity and showed no effect on male or female fertility. Lamivudine induces early embryolethality when administered to pregnant rabbits at exposure levels comparable to those achieved in man, but not in the rat even at very high systemic exposures.

The results of long term carcinogenicity studies with lamivudine in rats and mice did not shown any carcinogenic potential.

6. **PHARMACEUTICAL PARTICULARS**
6.1 List of excipients

Tablet core
Microcrystalline cellulose
Sodium starch glycolate (Type A)
Magnesium stearate

Tablet film coat
Hyromellose 3cP
Hyromellose 6cP
Titanium dioxide
Macrogol 400
Polysorbate 80
Iron oxide yellow
Iron oxide red

6.2 Incompatibilities

Not applicable

6.3 Shelf life

2 years

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Blisters:
White opaque PVC/PVdC – Aluminium blisters
Pack sizes of 28, 30, 84 or 100 film-coated tablets

Containers:

White opaque HDPE tablet containers with white opaque polyethylene child resistant screw cap with induction seal
Pack size of 60 film-coated tablets

White opaque HDPE tablet containers with white opaque polypropylene child resistant, tamper-evident screw cap with induction seal
Pack size of 60 film-coated tablets

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Teva B.V.
8. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/09/566/001 – 28 Tablets
EU/1/09/566/002 – 30 Tablets
EU/1/09/566/003 – 84 Tablets
EU/1/09/566/004 – 100 Tablets
EU/1/09/566/005 – 60 Tablets (bottle)
EU/1/09/566/006 – 60 Tablets (bottle with tamper evident cap)

9. **DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 23 October 2009
Date of latest renewal: 09 September 2014

10. **DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency [http://www.ema.europa.eu](http://www.ema.europa.eu)
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Teva Pharmaceutical Works Private Limited Company
Pallagi út 13
Debrecen H-4042
Hungary

Pharmachemie B.V.
Swensweg 5
2031 GA Haarlem
The Netherlands

Teva Operations Poland Sp.z o. o.
Mogilska 80 Str.
31-546 Kraków
Poland

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)
The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)
Not applicable.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

carton

1. NAME OF THE MEDICINAL PRODUCT

Lamivudine Teva 100 mg film-coated tablets
Lamivudine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 100 mg of lamivudine

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Blisters:
28 film-coated tablets
30 film-coated tablets
84 film-coated tablets
100 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use

Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands

<table>
<thead>
<tr>
<th>12. <strong>MARKETING AUTHORISATION NUMBER(S)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/09/566/001 – 28 Tablets</td>
</tr>
<tr>
<td>EU/1/09/566/002 – 30 Tablets</td>
</tr>
<tr>
<td>EU/1/09/566/003 – 84 Tablets</td>
</tr>
<tr>
<td>EU/1/09/566/004 – 100 Tablets</td>
</tr>
</tbody>
</table>

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Lamivudine Teva 100 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC
SN
NN
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

Immediate packaging (blister foil)

1. NAME OF THE MEDICINAL PRODUCT

Lamivudine Teva 100 mg film-coated tablets
Lamivudine

2. NAME OF THE MARKETING AUTHORISATION HOLDER

TEVA B.V.

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING

Tablet container

1. NAME OF THE MEDICINAL PRODUCT

Lamivudine Teva 100 mg film-coated tablets
Lamivudine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 100 mg of lamivudine

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Tablet container:
60 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use

Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
### 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Teva B.V.  
Swensweg 5  
2031GA Haarlem  
Netherlands

### 12. MARKETING AUTHORISATION NUMBER(S)

EU/1/09/566/005  
EU/1/09/566/006

### 13. BATCH NUMBER

Lot

### 14. GENERAL CLASSIFICATION FOR SUPPLY

### 15. INSTRUCTIONS ON USE

### 16. INFORMATION IN BRAILLE

Outer packaging (carton):  
Lamivudine Teva 100 mg

Immediate packaging (bottle label):  
**In case no outer packaging is used**  
Lamivudine Teva 100 mg

### 17. UNIQUE IDENTIFIER – 2D BARCODE

Outer packaging (carton):  
2D barcode carrying the unique identifier included.

Immediate packaging (bottle label):  
**In case no outer packaging is used**  
<2D barcode carrying the unique identifier included.>

### 18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

Outer packaging (carton):  
PC  
SN  
NN

Immediate packaging (bottle label):  
**In case no outer packaging is used**  
<PC  
SN
B. PACKAGE LEAFLET
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Lamivudine Teva is and what it is used for
2. What you need to know before you take Lamivudine Teva
3. How to take Lamivudine Teva
4. Possible side effects
5. How to store Lamivudine Teva
6. Contents of the pack and other information

1. What Lamivudine Teva is and what it is used for

The active ingredient in Lamivudine Teva is lamivudine.

Lamivudine Teva is used to treat long term (chronic) hepatitis B infection in adults.

Lamivudine Teva is an antiviral medicine that suppresses the hepatitis B virus and belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).

Hepatitis B is a virus which infects the liver causes long term (chronic) infection, and can lead to liver damage. Lamivudine Teva can be used in people whose liver is damaged but still functions normally (compensated liver disease) and in combination with other medicines in people whose liver is damaged and does not function normally (decompensated liver disease).

Treatment with Lamivudine Teva can reduce the amount of hepatitis B virus in your body. This should lead to a reduction in liver damage and an improvement in your liver function. Not everyone responds to treatment with Lamivudine Teva in the same way. Your doctor will monitor the effectiveness of your treatment with regular blood tests.

2. What you need to know before you take Lamivudine Teva

Do not take Lamivudine Teva

- if you are allergic to lamivudine or any of the other ingredients of this medicine (listed in section 6).

➔ Check with your doctor if you think this applies to you.

Warnings and precautions

Some people taking Lamivudine Teva or other similar medicines are more at risk of serious side effects. You need to be aware of the extra risks:
- if you have ever had other types of liver disease, such as hepatitis C.
- if you are seriously overweight (especially if you are a woman).
Talk to your doctor if any of these apply to you. You may need extra check-ups, including blood tests, while you are taking your medication. See section 4 for more information about the risks.

Do not stop taking Lamivudine Teva without your doctor’s advice, as there is a risk of your hepatitis getting worse. When you stop taking Lamivudine Teva your doctor will monitor you for at least four months to check for any problems. This will mean taking blood samples to check for any raised liver enzyme levels, which may indicate liver damage. See section 3 for more information about how to take Lamivudine Teva.

Protect other people
Hepatitis B infection is spread by sexual contact with someone who has the infection, or by transfer of infected blood (for example, by sharing injection needles). Lamivudine Teva will not stop you passing hepatitis B infection on to other people. To protect other people from becoming infected with hepatitis B:
• Use a condom when you have oral or penetrative sex.
• Do not risk blood transfer — for example, do not share needles.

Other medicines and Lamivudine Teva
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including herbal medicines or other medicines you bought without a prescription.

These medicines should not be used with Lamivudine Teva:
• medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly
• other medicines containing lamivudine, used to treat HIV infection (sometimes called the AIDS virus)
• emtricitabine (used to treat HIV or hepatitis B infection)
• cladribine, used to treat hairy cell leukaemia
⇒ Tell your doctor if you are being treated with any of these.

Pregnancy and breast-feeding
If you are pregnant, think you may be pregnant or are planning to have a baby:
⇒ Talk to your doctor about the risks and benefits of taking Lamivudine Teva during your pregnancy.
Do not stop treatment with Lamivudine Teva without your doctor’s advice.

Lamivudine Teva can pass into breast-milk. If you are breast-feeding, or thinking about breast-feeding:
⇒ Talk to your doctor before you take Lamivudine Teva.

Driving and using machines
Lamivudine Teva may make you feel tired, which could affect your ability to drive or use machines.
⇒ Don’t drive or use machines unless you are sure you’re not affected.

Lamivudine Teva contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially “sodium-free”.

3. How to take Lamivudine Teva

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Stay in regular contact with your doctor
Lamivudine Teva helps to control your hepatitis B infection. You need to keep taking it every day to control your infection and stop your illness getting worse.

⇒ Keep in touch with your doctor, and do not stop taking Lamivudine Teva without your doctor’s advice.

How much to take
The usual dose of Lamivudine Teva is one tablet (100 mg lamivudine) once a day.

Your doctor may prescribe a lower dose if you have problems with your kidneys. An oral solution of Lamivudine is available for people who need a lower than usual dose, or who can’t take tablets.

⇒ Talk to your doctor if this applies to you.

If you are already taking another medicine that contains lamivudine for HIV infection, your doctor will continue to treat you with the higher dose, (usually 150 mg twice a day), because the dose of lamivudine in Lamivudine Teva (100 mg) is not enough to treat HIV infection. If you are planning to change your HIV treatment, discuss this change with your doctor first.

Swallow the tablet whole, with some water. Lamivudine Teva can be taken with or without food.

If you take more Lamivudine Teva than you should
If you accidentally take too much Lamivudine Teva, tell your doctor or pharmacist, or contact your nearest hospital emergency department for further advice. If possible, show them the Lamivudine Teva pack.

If you forget to take Lamivudine Teva
If you forget to take a dose, take it as soon as you remember. Then continue your treatment as before. Do not take a double dose to make up for a forgotten dose.

Do not stop taking Lamivudine Teva
You must not stop taking Lamivudine Teva without consulting your doctor. There is a risk of your hepatitis getting worse (see section 2). When you stop taking Lamivudine Teva your doctor will monitor you for at least four months to check for any problems. This will mean taking blood samples to check for any raised liver enzyme levels, which may indicate liver damage.

4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.

Side effects that were commonly reported in Lamivudine clinical trials were tiredness, respiratory tract infections, throat discomfort, headache, stomach discomfort and pain, nausea, vomiting and diarrhoea, increases in liver enzymes and enzymes produced in the muscles (see below).

Allergic reaction
These are rare (may affect up to 1 in 1,000 people). Signs include:

- swelling of eyelids, face or lips
- difficulty swallowing or breathing

⇒ Contact a doctor immediately if you get these symptoms. Stop taking Lamivudine Teva.

Side effects thought to be caused by Lamivudine Teva

A very common side effect (these may affect more than 1 in 10 people) which may show up in blood tests is:
• an increase in the level of some liver enzymes (transaminases), which may be a sign of inflammation or damage in the liver.

A common side effect (these may affect up to 1 in 10 people) is:
• cramps and muscle pains
• skin rash or ‘hives’ anywhere on the body.

A common side effect which may show up in blood tests is:
• an increase in the level of an enzyme produced in the muscles (creatine phosphokinase) which may be a sign that body tissue is damaged.

A very rare side effect (these may affect up to 1 in 10,000 people) is:
• lactic acidosis (excess lactic acid in the blood).

Other side effects
Other side effects have occurred in a very small number of people but their exact frequency is unknown
• breakdown of muscle tissue
• a worsening of liver disease after Lamivudine Teva is stopped or during treatment if the hepatitis B virus becomes resistant to Lamivudine Teva. This can be fatal in some people.

A side effect which may show up in blood tests is:
• a decrease in the number of cells involved in blood clotting (thrombocytopenia).

If you get any side effects
➔ Talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Lamivudine Teva

Keep this medicine out of the sight and reach of children.

Do not take this medicine after the expiry date which is stated on the container or carton and blister pack after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions

Do not use Lamivudine Teva if you notice any change in the appearance of the tablet.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Lamivudine Teva contains
- The active substance is lamivudine. Each film-coated tablet contains 100 mg of lamivudine.
- The other ingredients are:
Tablet core: Microcrystalline cellulose, sodium starch glycolate, magnesium stearate. Tablet film coat: Hypromellose, titanium dioxide (E171), macrogol, polysorbate 80, iron oxide yellow (E172), iron oxide red (E172).

What Lamivudine Teva looks like and contents of the pack

Orange, capsule shaped, biconvex film-coated tablet – engraved with “L100” on one side and plain on the other

Lamivudine Teva is available in aluminium blisters containing 28, 30, 84 or 100 tablets or HDPE containers containing 60 tablets.

Not all pack sizes may be available in your country.

Marketing Authorisation Holder

Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands

Manufacturer

Teva Pharmaceutical Works Private Limited Company
Pallagi út 13
Debrecen H-4042
Hungary

Pharmacemie B.V.
Swensweg 5
2031 GA Haarlem
The Netherlands

Teva Operations Poland Sp.z o. o.
Mogilska 80 Str.
31-546 Kraków
Poland

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder
Danmark
Teva Denmark A/S
Tlf: +45 44985511

Malta
Teva Pharmaceuticals Ireland
L-Irlanda
Tel: +44 2075407117

Deutschland
TEVA GmbH
Tel: +49 73140208

Nederland
Teva Nederland B.V.
Tel: +31 8000228400

Eesti
UAB Teva Baltics Eesti filiaal
Tel: +372 6610801

Norge
Teva Norway AS
Tlf: +47 66775590

Ελλάδα
Specifar A.B.E.E.
Τηλ: +30 2118805000

Österreich
ratiopharm Arzneimittel Vertriebs-GmbH
Tel: +43 1970070

España
Teva Pharma, S.L.U.
Tel: +34 913873280

Portugal
Teva Pharma - Produtos Farmacêuticos, Lda.
Tel: +351 214767550

France
Teva Santé
Tél: +33 155917800

Polska
Teva Pharmaceuticals Polska Sp. z o.o.
Tel: +48 223459300

Ireland
Teva Pharmaceuticals Ireland
Tel: +44 2075407117

România
Teva Pharmaceuticals S.R.L.
Tel: +40 212306524

Hrvatska
Pliva Hrvatska d.o.o.
Tel: +385 13720000

Slovenija
Pliva Ljubljana d.o.o.
Tel: +386 15890390

İsland
Teva Pharma Iceland ehf.
Sími: +354 5503300

Slovenská republika
TEVA Pharmaceuticals Slovakia s.r.o.
Tel: +421 257267911

Italia
Teva Italia S.r.l.
Tel: +39 028917981

Suomi/Finland
Teva Finland Oy
Puh/Tel: +358 201805900

Κύπρος
Specifar A.B.E.E.
Ελλάδα
Τηλ: +30 2118805000

Sverige
Teva Sweden AB
Tel: +46 42121100

Latvija
UAB Teva Baltics filiāle Latvijā
Tel: +371 67323666

United Kingdom (Northern Ireland)
Teva Pharmaceuticals Ireland
Ireland
Tel: +44 2075407117

This leaflet was last revised in {MM/YYYY}.

Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu